Sorrento Therapeutics (SRNE) Competitors $0.0053 +0.00 (+51.43%) As of 03:40 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. EVOK, PRTG, OBSV, BCLI, KZIA, SNOA, BMRA, GNPX, VYNE, and ADILShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Evoke Pharma (EVOK), Portage Biotech (PRTG), ObsEva (OBSV), Brainstorm Cell Therapeutics (BCLI), Novogen (KZIA), Sonoma Pharmaceuticals (SNOA), Biomerica (BMRA), GENPREX (GNPX), VYNE Therapeutics (VYNE), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors Evoke Pharma Portage Biotech ObsEva Brainstorm Cell Therapeutics Novogen Sonoma Pharmaceuticals Biomerica GENPREX VYNE Therapeutics Adial Pharmaceuticals Sorrento Therapeutics (NASDAQ:SRNE) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Which has more risk and volatility, SRNE or EVOK? Sorrento Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Do insiders & institutionals have more ownership in SRNE or EVOK? 0.0% of Sorrento Therapeutics shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 6.1% of Evoke Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings & valuation, SRNE or EVOK? Evoke Pharma has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.05-$572.84MN/AN/AEvoke Pharma$10.25M0.79-$5.35M-$2.56-2.02 Does the media prefer SRNE or EVOK? In the previous week, Evoke Pharma had 2 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 2 mentions for Evoke Pharma and 0 mentions for Sorrento Therapeutics. Evoke Pharma's average media sentiment score of 0.69 beat Sorrento Therapeutics' score of 0.00 indicating that Evoke Pharma is being referred to more favorably in the news media. Company Overall Sentiment Sorrento Therapeutics Neutral Evoke Pharma Positive Is SRNE or EVOK more profitable? Sorrento Therapeutics has a net margin of 0.00% compared to Evoke Pharma's net margin of -42.07%. Sorrento Therapeutics' return on equity of 0.00% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A Evoke Pharma -42.07%-99.48%-33.58% SummarySorrento Therapeutics beats Evoke Pharma on 6 of the 11 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.92M$291.50M$5.69B$10.27BDividend YieldN/AN/A5.72%4.60%P/E RatioN/AN/A75.8626.51Price / Sales0.05431.33489.92165.32Price / CashN/A22.4425.8129.89Price / BookN/A10.4412.846.32Net Income-$572.84M-$111.61M$3.28B$270.51M7 Day PerformanceN/A-2.02%0.20%2.15%1 Month PerformanceN/A3.60%4.59%6.35%1 Year PerformanceN/A-14.21%68.31%25.48% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.9101 of 5 stars$0.01+51.4%N/A-22.2%$2.92M$60.32M0.00800Gap UpHigh Trading VolumeEVOKEvoke Pharma0.1417 of 5 stars$5.20-0.2%N/A+17.6%$8.12M$10.25M-2.034Short Interest ↑Gap DownPRTGPortage Biotech0.6199 of 5 stars$7.63+9.6%N/A+114.3%$8.01MN/A-0.186Gap UpHigh Trading VolumeOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050BCLIBrainstorm Cell Therapeutics1.3441 of 5 stars$0.70-1.4%N/A-83.3%$7.84MN/A-0.2140Positive NewsGap UpKZIANovogen3.6907 of 5 stars$7.71-0.7%$14.00+81.6%-53.4%$7.82M$1.51M0.0012Short Interest ↓Gap UpSNOASonoma Pharmaceuticals0.7826 of 5 stars$4.57-3.4%N/A+26.6%$7.77M$14.29M-1.86180BMRABiomerica0.6812 of 5 stars$2.91+5.8%N/A+23.3%$7.74M$5.31M-1.2560GNPXGENPREX1.209 of 5 stars$0.21-10.4%N/A-34.5%$7.68MN/A0.0020News CoverageShort Interest ↑Gap UpHigh Trading VolumeVYNEVYNE Therapeutics2.7719 of 5 stars$0.29-2.5%$6.25+2,043.3%-83.4%$7.62M$500K-0.3230Short Interest ↓ADILAdial Pharmaceuticals2.9576 of 5 stars$0.35+0.3%$8.00+2,189.0%-67.6%$7.61MN/A-0.3320News CoveragePositive NewsShort Interest ↓Gap Up Related Companies and Tools Related Companies Evoke Pharma Competitors Portage Biotech Competitors ObsEva Competitors Brainstorm Cell Therapeutics Competitors Novogen Competitors Sonoma Pharmaceuticals Competitors Biomerica Competitors GENPREX Competitors VYNE Therapeutics Competitors Adial Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRNE Stock Alerts